Document Detail

Compounding pharmacy conundrum: "we cannot live without them but we cannot live with them" according to the present paradigm.
MedLine Citation:
PMID:  23412546     Owner:  NLM     Status:  MEDLINE    
Compounding pharmacies serve a critical role in modern health care to meet special patient care needs. Although the US Food and Drug Administration (FDA) has clearly delineated jurisdiction over drug companies and products manufactured under Good Manufacturing Practice (GMP) regulations to ensure quality, potency, and purity, compounding pharmacies are regulated by the State Boards and are not registered by the FDA. In recent years, some compounding pharmacies acted like a manufacturer, preparing large amounts of injectable drugs with interstate activities. Multiple outbreaks have been linked to compounding pharmacies, including a recent outbreak of fungal meningitis related to contaminated methylprednisolone, exposing > 14,000 patients in multiple states. This tragedy underscores the urgency of addressing safety related to compounding pharmacies. There is a call for action at the federal and state levels to set minimum production standards, impose new labeling conditions on compounded drugs, and require large-scale compounders be regulated by the FDA. "Industrial" compounding must come under FDA oversight, require those pharmacies to meet GMP standards, and ensure quality and safe products for patient use. Moreover, compliance with the Institute for Safe Medication Practices 2011 recommendations that any type of sterile compounding must be in compliance with the United States Pharmacopoeia chapter 797 guidelines will reduce the risk of patient harm from microbial contamination. Finally, other critical factors that require close attention include addressing injectable products compounded in hospitals and other outpatient health-care centers. The FDA and State Boards of Pharmacy must be adequately funded to exercise the oversight effectively.
Roy Guharoy; John Noviasky; Ziad Haydar; Mohamad G Fakih; Christian Hartman
Related Documents :
23584056 - Application scope and limitations of taddol-derived chiral ammonium salt phase-transfer...
2170036 - Synthesis and antiulcer activity of 4-substituted 8-[(2-benzimidazolyl)sulfinylmethyl]-...
24778726 - Phosphinate-containing heterocycles: a mini-review.
24989456 - A metal-free three-component reaction for the regioselective synthesis of 1,4,5-trisubs...
23239266 - Copper-catalyzed intramolecular oxidative ch functionalization and cn formation o...
24213526 - Preparation and characterization of a novel wells-dawson heteropolyacid-based magnetic ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Chest     Volume:  143     ISSN:  1931-3543     ISO Abbreviation:  Chest     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-04-02     Completed Date:  2013-07-08     Revised Date:  2013-12-24    
Medline Journal Info:
Nlm Unique ID:  0231335     Medline TA:  Chest     Country:  United States    
Other Details:
Languages:  eng     Pagination:  896-900     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Drug Compounding / standards*
Drug Contamination / prevention & control*
Drug Industry / legislation & jurisprudence*,  standards*
Guidelines as Topic
Patient Safety
Risk Factors
United States
United States Food and Drug Administration
Comment In:
Chest. 2013 Aug;144(2):717   [PMID:  23918132 ]
Chest. 2013 Aug;144(2):717-8   [PMID:  23918133 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A Heritable Recombination System for Synthetic Darwinian Evolution in Yeast.
Next Document:  The Effects of Four Different Recovery Strategies on Repeat Sprint Cycling Performance.